Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in diagnostic dealmaking

2.1. Introduction
2.2. Diagnostic partnering over the years
2.3. Most active diagnostic dealmakers
2.4. Bigpharma diagnostic dealmaking activity
2.5. Bigpharma not active in diagnostics
2.6. Diagnostics partnering by deal type
2.7. Diagnostics partnering by stage of development
2.8. Diagnostics partnering by disease type

2.9. Average deal terms for diagnostics partnering
2.9.1 Diagnostics partnering headline values
2.9.2 Diagnostic deal upfront payments
2.9.3 Diagnostics royalty rates

2.10. The anatomy of diagnostic partnering
2.10.1. The anatomy of a diagnostic deal
2.10.1.a. Case study 1: Sequenom - Lenetex - January 2007
2.10.1.b. Case study 2: Celera - Siemens Medical Solutions - July 2007
2.10.1.c. Case study 3: US Genomics - Rosetta Genomics - May 2006

2.11. Litigation and settlement in diagnostics

Chapter 3 - Leading diagnostic deals

3.1. Introduction
3.2. Top diagnostic deals by value
3.3. Top diagnostic deals involving bigpharma
3.4. Leading diagnostics M&A deals by value

Chapter 4 - Bigpharma diagnostic deals

4.1. Introduction
4.2. How to use bigpharma diagnostic partnering deals

4.3. Bigpharma partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson

Chapter 5 - Diagnostic dealmaking directory

5.1. Introduction

5.2. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

5.3. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Interests
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

5.4. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hormonal
Hospital care
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organs

Chapter 6 - Diagnostic partnering resource center

6.1. Online diagnostic partnering
6.2. Diagnostic partnering events
6.3. Further reading on diagnostic dealmaking

Appendices

Appendix 1 - Deal type definitions
Appendix 2 - Example diagnostics partnering agreement

About CurrentPartnering
Recent titles from CurrentPartnering
Order Form - Reports

List of Figures

Figure 1: Diagnostic partnering since 2007
Figure 2: Most active diagnostic dealmakers 2007-2011
Figure 3: Bigpharma - top 50 - diagnostic deals 2007 to 2011
Figure 4: Bigpharma diagnostic deal frequency - 2007 to 2011
Figure 5: Inactive bigpharma in diagnostic dealmaking 2007-2011
Figure 6: Diagnostics partnering by deal type since 2007
Figure 7: Diagnostics partnering by stage of development since 2007
Figure 8: Diagnostics partnering by disease type since 2007
Figure 9: Diagnostics partnering by oncology target since 2007
Figure 10: Diagnostic deals with a headline value - by stage of development
Figure 11: Diagnostic deal headline value distribution - discovery stage, US$million
Figure 12: Diagnostic deal headline value distribution - discovery stage, US$million - detail
Figure 13: Diagnostic deal headline value distribution - preclinical stage, US$million
Figure 14: Diagnostic deal headline value distribution - preclinical stage, US$million
Figure 15: Diagnostic deals with upfront payment values - by stage of development
Figure 16: Diagnostic deal upfront payment distribution - discovery stage, US$million
Figure 17: Diagnostic deal upfront payment distribution - discovery stage, US$million - detail
Figure 18: Diagnostic deals with milestone payments
Figure 19: Diagnostic deal milestone payment distribution, US$million
Figure 20: Diagnostic deals with royalty rates
Figure 21: Components of the typical diagnostic deal structure
Figure 22: Settlement licensing agreements since 2003
Figure 23: Top diagnostic deals by value since 2007
Figure 24: Top diagnostic deals signed by bigpharma value since 2007
Figure 25: Top diagnostic M&A deals by value since 2007
Figure 26: Diagnostic deals by therapy - cardiovascular - 2007 - 2011
Figure 27: Diagnostic deals by therapy - central nervous system - 2007 - 2011
Figure 28: Diagnostic deals by therapy - dental - 2007 - 2011
Figure 29: Diagnostic deals by therapy - dermatology - 2007 - 2011
Figure 30: Diagnostic deals by therapy - gastrointestinal - 2007 - 2011
Figure 31: Diagnostic deals by therapy - genetic disorders - 2007 - 2011
Figure 32: Diagnostic deals by therapy - genitourinary - 2007 - 2011
Figure 33: Diagnostic deals by therapy - hematology - 2007 - 2011
Figure 34: Diagnostic deals by therapy - hormonal - 2007 - 2011
Figure 35: Diagnostic deals by therapy - hospital care - 2007 - 2011
Figure 36: Diagnostic deals by therapy - immunology - 2007 - 2011
Figure 37: Diagnostic deals by therapy - infectives - 2007 - 2011
Figure 38: Diagnostic deals by therapy - inflammatory - 2007 - 2011
Figure 39: Diagnostic deals by therapy - metabolic - 2007 - 2011
Figure 40: Diagnostic deals by therapy - musculoskeletal - 2007 - 2011
Figure 41: Diagnostic deals by therapy - oncology - 2007 - 2011
Figure 42: Diagnostic deals by therapy - ophthalmics - 2007 - 2011
Figure 43: Diagnostic deals by therapy - respiratory - 2007 - 2011
Figure 44: Diagnostic deals by therapy - sensory organs - 2007 - 2011
Figure 45: Online partnering resources
Figure 46: Forthcoming partnering events
Figure 47: Deal type definitions
Figure 48: Diagnostics partnering agreement between Inhibitex and 3M, February 2007